Loading...
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
Although imatinib has dramatically improved major outcomes in patients with chronic myeloid leukemia (CML), there are newer tyrosine kinase inhibitors (TKIs) approved worldwide for the treatment of resistant cases, and two second-generation TKIs (dasatinib, nilotinib) are approved in some nations fo...
Saved in:
| Published in: | Ther Adv Hematol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5639974/ https://ncbi.nlm.nih.gov/pubmed/29051802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717719851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|